Introduction
Metal prosthesis produce streaking artifacts in patient CT images which affect the delineation of prostate target volume and dose calculations. Sometimes the artifacts surrounding metal hips are too severe for physicians to make accurate contouring. At this situation, expanding the PTV contours based on physician's best guess is clinically practical. In this work, we use Bazalova's artifact-correction algorithm 1 to obtain less metal-artifact CT images for prostate patients with metal prosthesis. New PTV contouring was made on the artifact -corrected CT images while an set of 3D ultrasound (U) images for prostate localization is also employed to help re-contouring the PTV volume. XV Monte Carlo method is used to re-calculate patient composite delivered dose on two patient phantoms derived from their artifact-degraded and artifact-corrected CT images, separately, while taking into account the patient heterogeneities, prostate's daily displacements and different delineations of target volume.
Method and Materials
Three treated prostate patients with two-side or one-side prosthesis have been respectively analyzed. An intra-modality 3D US localization system (Restitu TM , Montreal, Canada) was used to aid delineating the prostate. The US images used to guide the delineating PTV on artifact degraded CT images were acquired at the same time of CT simulation at the simulation room. Conformal RT treatment plans were developed based on target volumes delineated on artifact degraded CT images (PTV a ). The patients' treatments were aided with same type of US localization system which was installed in treatment room for daily PTV setup correction. We retrospectively re-evaluated the delineation of PTVs by 1) using simulation CT images artifact-corrected by using an algorithm developed by M. Bazalova et al (2007) (PTV c ) and 2) using the 3D ultrasound simulation images as guide (PTV us ). We then incorporated daily setup correction parameters to the PTVs to calculate composite delivered dose by using XVMC simulation on the patient phantoms derived from the artifact-degraded and artifactcorrected CT images. The two composite doses are called DOSE artifact and DOSE corrected , separately. DOSE artifact is regarded as the reference treatment plan, because it carries all the treatment parameters of the original treatment plan. DVHs and dose distributions for different PTVs were then compared between and DOSE corrected and DOSE artifact .
Results:
The PTV a volume PTV is the largest, about 1.3 % larger than PTV a and 5.2% larger than PTV us , as listed in Table 1 The top panels show comparisons of isodose curves and DVH curves between DOSE corrected and DOSE artifact .for one patient. A large difference is found in the 100% isodose curve. DOSE corrected predicts higher dose than DOSE artifact for the PTV c , bladder and rectum. The right top panel shows that adopting artifact-corrected CT images can improve the DVH curves of PTV c and the left bottom table demonstrates that increases the D95% and V95% of PTV c are increased by more than 5% due to artifact correction. The right bottom panel displays a small difference in the changes of their DVH indices between artifact-degraded PTV and US-aided PTV, less than 4% for three studied patients.
Isodose curve comparison between DOSE corrected and DOSE artifact between DOSE corrected and DOSE artifact Conclusion The strike artifacts from metal prosthesis will increase the volume of PTV, and affect the patient dose calculation. Original patient plans did not accurately predict the dose degradation due to metal artifact. Artifact correction may be necessary for some cases with severe metal artifact. Using US images to help accurately delineating PTV makes a negligible clinical significance in term of DVH indices.
